-
Product Insights
NewNet Present Value Model: Immunic Inc’s Vidofludimus calcium
Empower your strategies with our Net Present Value Model: Immunic Inc's Vidofludimus calcium report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
NewImmune IQ Pipeline Insight and Competitive Landscape, 2024
Empower your strategies with our Immune IQ Pipeline Insight and Competitive Landscape, 2024 report and make more profitable business decisions. Immune IQ a medical equipment company which develops point-of-care medical diagnostic technologies for various medical applications in healthcare settings and offers other related products. The company is headquartered in Saint Paul, Minnesota, the US. GlobalData's Medical Devices company profile report, “Immune IQ Pipeline Insight and Competitive Landscape, 2024" provides information about the company overview and analysis on their pipeline products....
-
Product Insights
NewNet Present Value Model: Alpine Immune Sciences Inc’s Povetacicept
Empower your strategies with our Net Present Value Model: Alpine Immune Sciences Inc's Povetacicept report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewAC Immune SA Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our AC Immune SA Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. AC Immune SA (AC Immune) is a clinical-stage biopharmaceutical company that discovers, designs and develops proprietary medicines to prevent, diagnose and treat neurodegenerative diseases associated with protein misfolding. The company develops drugs based on its two proprietary technology platforms: SupraAntigen and Morphomer. Its technology platforms help the company to design, discover and develop antibodies, small molecules and vaccines. AC...
-
Product Insights
Innovations in Auto-Immune Diseases – Global Pipeline Summary
GlobalData's Medical Devices sector report, "Innovations in Auto-Immune Diseases - Global Pipeline Summary" provides comprehensive information about the Auto-Immune Diseases pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. The Auto-Immune Diseases report provides key information and data related to: Extensive coverage of the Auto-Immune Diseases under development Review details of major pipeline products which include product description, licensing and collaboration details and other developmental activities including pipeline territories,...
-
Innovation Ranking
Innovation Ranking – Alpine Immune Sciences Inc
Alpine Immune Sciences Inc (Alpine), formerly Nivalis Therapeutics Inc, is a pharmaceutical company. The company focuses on discovering and developing protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. It provides ALPN-101 and ALPN-303 for the treatment of based immunotherapies and immune synapses to treat cancer and autoimmune and inflammatory diseases. The company also provides ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer. It offers a proprietary scientific platform that converts native immune...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TAK-881 in Primary Immune Deficiency (PID)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TAK-881 in Primary Immune Deficiency (PID) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TAK-881 in Primary Immune Deficiency (PID) Drug Details: TAK-881...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BT-595 in Primary Immune Deficiency (PID)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BT-595 in Primary Immune Deficiency (PID) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BT-595 in Primary Immune Deficiency (PID) Drug Details: Human...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cevidoplenib in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cevidoplenib in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cevidoplenib in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Povetacicept in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Povetacicept in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Povetacicept in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic...